Vetoquinol SA (0O1O.L)

EUR 76.9

(0.0%)

EBITDA Summary of Vetoquinol SA

  • Vetoquinol SA's latest annual EBITDA in 2023 was 104.58 Million EUR , down -31.0% from previous year.
  • Vetoquinol SA's latest quarterly EBITDA in 2024 Q2 was 44.71 Million EUR , down 0.0% from previous quarter.
  • Vetoquinol SA reported an annual EBITDA of 103.45 Million EUR in 2022, up 0.65% from previous year.
  • Vetoquinol SA reported an annual EBITDA of 116.85 Million EUR in 2021, up 40.54% from previous year.
  • Vetoquinol SA reported a quarterly EBITDA of 51.42 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Vetoquinol SA reported a quarterly EBITDA of 34.85 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of Vetoquinol SA (2023 - 2005)

Historical Annual EBITDA of Vetoquinol SA (2023 - 2005)

Year EBITDA EBITDA Growth
2023 104.58 Million EUR -31.0%
2022 103.45 Million EUR 0.65%
2021 116.85 Million EUR 40.54%
2020 59.29 Million EUR 33.3%
2019 58.79 Million EUR -2.04%
2018 60.01 Million EUR 5.13%
2017 57.09 Million EUR 2.83%
2016 55.52 Million EUR 8.21%
2015 51.3 Million EUR 8.27%
2014 51.1 Million EUR 6.71%
2013 44.4 Million EUR 1.95%
2012 43.61 Million EUR -1.63%
2011 45.28 Million EUR -3.08%
2010 43.33 Million EUR -10.9%
2009 36.47 Million EUR 6.64%
2008 37.79 Million EUR 26.13%
2007 38.54 Million EUR 26.98%
2006 33.25 Million EUR 1.05%
2005 26.67 Million EUR 0.0%

Peer EBITDA Comparison of Vetoquinol SA

Name EBITDA EBITDA Difference
Boiron SA 80.67 Million EUR -29.626%
Laboratorios Farmaceuticos Rovi, S.A. 238.01 Million EUR 56.062%
Valneva SE -64.51 Million EUR 262.098%
AB Science S.A. -9.28 Million EUR 1226.829%
Nanobiotix S.A. -34.01 Million EUR 407.419%
PHAXIAM Therapeutics S.A. -22.93 Million EUR 556.088%
Vivoryon Therapeutics N.V. -28.35 Million EUR 468.853%
BioSenic S.A. -6.79 Million EUR 1638.861%
ABIVAX Société Anonyme -133.2 Million EUR 178.51%
Formycon AG 81.05 Million EUR -29.028%